Influence of hydrogen-bonding substituents on the cytotoxicity of RAPTA compounds

被引:155
作者
Scolaro, C
Geldbach, TJ
Rochat, S
Dorcier, A
Gossens, C
Bergamo, A
Cocchietto, M
Tavernelli, I
Sava, G
Rothlisberger, U
Dyson, PJ
机构
[1] Callerio Fdn Onlus, I-34127 Trieste, Italy
[2] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
[3] Univ Trieste, Dipartimento Sci Biomed, I-34127 Trieste, Italy
关键词
D O I
10.1021/om0508841
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
A new series of organometallic ruthenium(II)-arene compounds of the type RuCl2(eta(6)-arene)(phosphine) (phosphine = 1,3,5-triaza-7-phosphaadamantane, PTA, and 3,7-diacetly-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane, DAPTA) with different potential hydrogen-bonding functionalities on the arene ligand have been prepared and studied for their antitumor activity. Cell viability studies using the TS/A mouse adenocarcinoma cancer cell line and the nontumorigenic HBL-100 human mammary cell line, combined with uptake determinations, are compared to the nonfunctionalized analogues, previously shown to be active on solid metastasizing tumors. The reactivity of the functionalized RAPTA compounds with a 14-mer oligonucleotide (established by mass spectrometry) has been rationalized by DFT calculations, which indicate that environmental factors are important.
引用
收藏
页码:756 / 765
页数:10
相关论文
共 64 条
[1]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[2]   Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA=1,3,5-triaza-7-phosphaadamantane) [J].
Akbayeva, DN ;
Gonsalvi, L ;
Oberhauser, W ;
Peruzzini, M ;
Vizza, F ;
Brüggeller, P ;
Romerosa, A ;
Sava, G ;
Bergamo, A .
CHEMICAL COMMUNICATIONS, 2003, (02) :264-265
[3]  
Alessio E, 2004, MET IONS BIOL SYST, V42, P323
[4]   Development of organometallic (organo-transition metal) pharmaceuticals [J].
Allardyce, CS ;
Dorcier, A ;
Scolaro, C ;
Dyson, PJ .
APPLIED ORGANOMETALLIC CHEMISTRY, 2005, 19 (01) :1-10
[5]   [Ru(η6-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane):: a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells [J].
Allardyce, CS ;
Dyson, PJ ;
Ellis, DJ ;
Heath, SL .
CHEMICAL COMMUNICATIONS, 2001, (15) :1396-1397
[6]  
ALLEY MC, 1988, CANCER RES, V48, P589
[7]   ENERGY-ADJUSTED ABINITIO PSEUDOPOTENTIALS FOR THE 2ND AND 3RD ROW TRANSITION-ELEMENTS [J].
ANDRAE, D ;
HAUSSERMANN, U ;
DOLG, M ;
STOLL, H ;
PREUSS, H .
THEORETICA CHIMICA ACTA, 1990, 77 (02) :123-141
[8]  
[Anonymous], CRYSALIS RED
[9]  
[Anonymous], 2003, GAUSS 03 REV B 03
[10]  
BARNARD CFJ, 1986, CHEM BRIT, V22, P1001